Finding actionable genetic alterations/mutations

Precision medicine is changing cancer care

The identification of actionable genetic alterations/mutations is becoming an essential strategy in the management of advanced cancers. A recent analysis found that nearly half of tumors harbor an actionable target.1 *

Targeted agents based on genetic alterations/mutations have proven effective in treating subsets of various malignancies, including breast cancer, non-small cell lung cancer, and melanoma.2-4

5 blue human icons. One has a green crescent with a blue bullseye over it. Targeting F G F R alterations

Specific genetic alterations/mutations can guide therapy in urothelial carcinoma

There are actionable genomic targets for certain patients who have progressed during or after at least one
line of prior systemic† therapy of locally advanced or metastatic urothelial carcinoma.5 Discover how the first and only approved 2L oral targeted therapy for locally advanced or mUC with FGFR3 mutations works.

*Single-arm, open-label study that evaluated the molecular profile of tumors from 843 patients with advanced cancers using high-throughput genomics. The most frequent tumor types included cancers of the digestive system (n=197), lung (n=170), urological system (n=158), breast (n=135), and head and neck (n=111).1
†Limitations of Use: BALVERSA® is not recommended for the treatment of patients who are eligible for and have not received prior PD-1 or PD-L1 inhibitor therapy.

2L = second-line; FDA = U.S. Food and Drug Administration; FGFR = fibroblast growth factor receptor; mUC = metastatic urothelial carcinoma; PD-L1/PD-1 = programmed death ligand 1/programmed cell death protein 1.

References

1. Massard C, Michiels S, Ferté C, et al. High-throughput genomics and clinical outcome in hard-to-treat advanced cancers: results of the MOSCATO 01 trial. Cancer Discov. 2017;7(6):586-595. 2. Geyer CE, Forster J, Lindquist D, et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med. 2006;355:2733-2743. 3. Peters S, Camidge DR, Shaw AT, et al. Alectinib versus crizotinib in untreated ALK-positive non–small-cell lung cancer. N Engl J Med. 2017;377:829-838. 4. Chapman PB, Robert C, Larkin J, et al. Vemurafenib in patients with BRAFV600 mutation-positive metastatic melanoma: final overall survival results of the randomized BRIM-3 study. Ann Oncol. 2017;28:2581-2587. 5. BALVERSA® [Prescribing Information]. Horsham, PA: Janssen Biotech, Inc.

Back to top
No footer content content fetched
No footer links content fetched